Show simple item record

dc.contributor.authorRuiz García, Juan 
dc.contributor.authorAlegría Barrero, Eduardo
dc.description.abstractAs drug development becomes a long and demanding process, it might also become a barrier to medical progress. Drug safety concerns are responsible for many of the resources consumed in launching a new drug. Despite the money and time expended on it, a significant number of drugs are withdrawn years or decades after being in the market. Cardiovascular toxicity is one of the major reasons for those late withdrawals, meaning that many patients are exposed to unexpected serious cardiovascular risks. It seems that current methods to assess cardiovascular safety are imperfect, so new approaches to avoid the exposure to those undesirable effects are quite necessary. Endothelial dysfunction is the earliest detectable pathophysiological abnormality, which leads to the development of atherosclerosis, and it is also an independent predictor for major cardiovascular events. Endothelial toxicity might be the culprit of the cardiovascular adverse effects observed with a significant number of drugs. In this article we suggest the regular inclusion of the best-validated and less invasive endothelial function tests in the clinical phases of drug development, in order to facilitate the development of drugs with safer cardiovascular profiles.eng
dc.publisherJournal of Cardiovascular Pharmacology and Therapeuticsspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.titleCardiovascular safety in drugs development: a aole for endothelial function
dc.description.extent236 KBspa

Files in this item

Cardiovascular Safety ruiz ...235.9KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España